SAR and Pharmacophore Based Designing of Some Antimalarial and Antiretroviral Agents: An INTERNET Based Drug Design Approach
With the development of computational chemistry and molecular docking studies SAR and pharmacophore based drug design have been modified to target based drug discovery using sophisticated computational tools which is not very much user friendly and has got many incompatibility issues with many operating systems(OS) and other system configurations. In this paper SAR (Structure Activity Relationship) and pharmacophore based drug design approaches have been described by the used of free internet based tools which are very much user friendly and can almost compatible with any platform. Some antimalarial. And anti retroviral agents have been designed using pharmacophore study and their drug like properties,toxicity,metabolic sites and other parameters are predicted by the free internet based tools.
Available from: Naresh Kandakatla
[Show abstract] [Hide abstract]
ABSTRACT: Histone deacetylases2, Class 1 HDAC family are emerged as an important
therapeutic target for the treatment of various cancers. HDAC2 inhibitors are
potent anti-cancer agents. Two inhibitors of HDAC2 are Hydroxamic acid and
Valporic acid which are potent inducers of growth arrest, differentiation, and/
or apoptotic cell death. Total 34 ligands optimized using Triazole group
substitution for the target protein Histone Deacetylase2 on the basis of SAHA
and Valporic acid. All the ligands are docked with the target protein and
results are compared with test compound SAHA. Eight ligands showed better
binding affinity towards HDAC2.The binding affinity, free energy and drug
scan screening of the above eight ligands have shown that P2, P6 and V6
molecules are best suitable to inhibit HDAC2.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.